COVID-19

SARS-CoV-2

One 60mg tablet P.O. once per day for 14 days

Pyridostigmine Bromide

Placebo

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

Pyridostigmine in Severe SARS-CoV-2 Infection

Pyridostigmine in Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2 Infection

Composite of death, Need for mechanical ventilation, or an increase of 2 or more points in the SOFA score

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Participants will receive pyridostigmine at a dose of 60 mg / day (or matching placebo), P.O. during a period of up to 14 days, until hospital discharge, death, mechanical ventilation, or increase in the SOFA scale ≥2 points.
The proposed dose is a safe dose according to the experience in myasthenia gravis and healthy people, as well as in at least three clinical studies in people living with HIV.
Participants will be double-blind 1: 1 randomized to receive pyridostigmine or placebo for up to 14 days.

Saline starting before induction till entry to abdominal cavity

Remifentanil starting before induction till entry to abdominal cavity

Pre-Eclampsia

Hypertension, Pregnancy-Induced

Pregnancy Complications

1 microg/kg iv bolus before induction followed by 0.5 microg/kg/min infusion

Remifentanil

same volume iv bolus before induction followed by same volume infusion

esterase/hypoxia

Pyridostigmine in Severe SARS-CoV-2 Infection

Remifentanil for General Anesthesia in Preeclamptics

Најкомплетнија база лековитог биља подржана науком